Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
GALAPAGOS, often referred to simply as Galapagos, is a prominent pharmaceutical company headquartered in the US, with significant operational presences across Europe. Specialising in Pharmaceutical Preparation Manufacturing, Galapagos is dedicated to discovering, developing, and commercialising innovative medicines for unmet medical needs.
Founded in 1999, Galapagos has rapidly evolved, becoming a clinical-stage biotechnology company with a robust pipeline. Their core focus lies in immunology, oncology, and other therapeutic areas, aiming to provide novel treatments that offer genuine improvements for patients.
Galapagos distinguishes itself through its unique target discovery platform and commitment to ground-breaking research. This approach has positioned them as a significant player in the biopharmaceutical landscape, known for their rigorous scientific methodology and potential to bring transformative therapies to market.
+26 vs industry average
GALAPAGOS’s score of 68 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
In 2025, GALAPAGOS reported total carbon emissions of approximately 34.5 million kg CO2e. This figure includes Scope 1 emissions of about 964,000 kg CO2e, Scope 2 emissions of approximately 88,000 kg CO2e (market-based), and a significant contribution from Scope 3 emissions, which totalled around 33.4 million kg CO2e. The Scope 3 emissions breakdown reveals major sources, including purchased goods and services (approximately 26.6 million kg CO2e) and processing of sold products (about 1.1 million kg CO2e).
In 2024, GALAPAGOS's emissions were approximately 49.3 million kg CO2e, with Scope 1 emissions at about 1.05 million kg CO2e, Scope 2 emissions of approximately 1.14 million kg CO2e (market-based), and Scope 3 emissions reaching around 48.1 million kg CO2e. The 2023 data indicates total emissions of about 39.6 million kg CO2e, with Scope 1 at approximately 2.9 million kg CO2e, Scope 2 at about 173,000 kg CO2e (market-based), and Scope 3 emissions at around 36.5 million kg CO2e.
Despite these figures, GALAPAGOS has not set specific reduction targets or climate pledges, indicating a potential area for future commitment. The emissions data is not cascaded from any parent organisation, ensuring that the reported figures are solely from GALAPAGOS NV.
No climate goals have been disclosed for GALAPAGOS yet.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more